Evidence map›Paper›PMID 37658334›Full record

ArticleBMC pulmonary medicine2023

Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study.

Takashi Kobayashi, Yoshikazu Nishino, Tomoya Takiguchi, Shintaro Kanda, Kengo Otsuki, Yuriko Tanaka, Yozo Nakazawa, Ken-Ichi Ito, Ryuji Hayashi, Kazuo Yasumoto and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Lung Cancer Outcomes in Vietnam: A 6-Year Retrospective Study.Journal of immunotherapy and precision oncology · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Takashi KobayashiDepartment of Hematology and Medical Oncology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Nagano, Japan.
Yoshikazu NishinoDepartment of Epidemiology and Public Health, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Tomoya TakiguchiDepartment of Epidemiology and Public Health, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Shintaro KandaDepartment of Hematology and Medical Oncology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Nagano, Japan.
Kengo OtsukiDepartment of Hematology and Medical Oncology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Nagano, Japan.
Yuriko TanakaDepartment of Hematology and Medical Oncology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Nagano, Japan.
Yozo NakazawaDepartment of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
Ken-Ichi ItoDivision of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Ryuji HayashiClinical Oncology, Toyama University Hospital, Toyama, Japan.
Kazuo YasumotoDepartment of Medical Oncology, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Hidetaka UramotoDepartment of Thoracic Surgery, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Yasuo HironoCancer Care Promotion Center, University of Fukui Hospital, Fukui, Japan.
Tomoe MakinoDivision of Adult Nursing Practice, Ishikawa Prefectural Nursing University, Kahoku, Japan.
Mitsutoshi NakadaDepartment of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Seiji YanoDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Tomonobu KoizumiDepartment of Hematology and Medical Oncology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Nagano, Japan. tomonobu@shinshu-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study was performed to validate the epidemiology, initial treatment, and clinical practice of lung cancer patients in the Hokushin region, Japan.

methodsWe retrospectively surveyed data of 5503 newly diagnosed and registered lung cancer patients in 22 principal hospital-based cancer registries in Hokushin region linked with health insurance claims data for registered patients between 2016 and 2017.

resultsThe patients consisted of 3677 (66.8%) men and 1826 (33.2%) women with a mean (range) age of 72.2 (27-103) years). Diagnoses were small cell lung cancer (n = 512, 9.4%), squamous cell carcinoma (n = 1083, 19.7%), and non-squamous non-small cell lung cancer (NSCLC; n = 3906, 70.9%). The population with stage I disease in Toyama prefecture (41.1%) was smaller than in the other three prefectures associated with reduced selection of initial surgical therapy and increased frequencies of stage IV disease (33.2%) and best supportive care (18.6%). Initial chemotherapy for stage IV non-squamous NSCLC consisted of tyrosine kinase inhibitors in 39.3% of cases for EGFR and 4% of cases for ALK-positive non-squamous NSCLC, followed by platinum compounds (25.9%) non-platinum compounds (12.9%), and immune checkpoint inhibitors (10.2%). Carboplatin was the commonly prescribed first-line cytotoxic chemotherapeutic agent (65.4% of patients under 75 years and in 96.7% of patients over 75 years).

conclusionThis study revealed real-world data on epidemiological and treatment status in lung cancer in four prefectures in Hokushin region, Japan. Simultaneous analysis of nationwide registry and insurance data could provide valuable insights for the development of lung cancer screening and medical treatment strategies. In addition, the comparative data analysis with other lesions or countries will be useful for evaluating the differences in clinical practice of cancer managements.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedAged, 80 and overEarly Detection of CancerFemaleHospitalsHumansJapanMaleRetrospective StudiesCancer registrationEarly-stage lung cancerHospital-based cancer registryLung cancer screening

Identifiers

PMID37658334
PMCPMC10472700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.